SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
HCA Healthcare, Inc. (HCA) trades at a trailing P/E of 17.2, forward P/E of 16.5. Trailing earnings yield is 5.80%, forward earnings yield 6.07%. PEG 0.59 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (61/100, Pass) — P/E is below market average (17.2); PEG ≤ 1.0 — Peter Lynch undervalued (0.59); earnings yield beats bond yields (5.80%).
- Forward P/E 16.5 (down from trailing 17.2) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.59 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 5.80% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 6.07% as earnings recover.
- Analyst consensus target $523.92 (+5.1% upside) — modest upside expected.
Overall SharesGrow Score: 61/100 with 5/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
61/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
25/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — HCA
Valuation Multiples
P/E (TTM)17.2
Forward P/E16.5
PEG Ratio0.59
Forward PEG2.50
P/B Ratio-19.40
P/S Ratio1.50
EV/EBITDA10.4
Per Share Data
EPS (TTM)$29.40
Forward EPS (Est.)$30.27
Book Value / Share$-12.01
Revenue / Share$327.68
FCF / Share$33.34
Yields & Fair Value
Earnings Yield5.80%
Forward Earnings Yield6.07%
Dividend Yield0.58%
SharesGrow IV$621.48 (+24.6%)
Analyst Target$523.92 (+5.1%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
9.5 |
0.21 |
-3.76 |
0.66 |
- |
| 2017 |
13.9 |
-0.74 |
-4.52 |
0.71 |
- |
| 2018 |
11.3 |
0.15 |
-8.62 |
0.91 |
1.14% |
| 2019 |
14.4 |
-2.06 |
-17.96 |
0.98 |
1.09% |
| 2020 |
14.9 |
1.89 |
97.59 |
1.08 |
0.27% |
| 2021 |
11.9 |
0.13 |
-89.03 |
1.41 |
0.75% |
| 2022 |
12.3 |
-1.28 |
-25.18 |
1.16 |
0.94% |
| 2023 |
14.1 |
-13.67 |
-41.56 |
1.13 |
0.90% |
| 2024 |
13.5 |
0.86 |
-31.06 |
1.10 |
0.89% |
| 2025 |
15.9 |
0.56 |
-17.87 |
1.42 |
0.63% |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$7.30 |
$41.49B |
$2.89B |
7% |
| 2017 |
$5.95 |
$43.61B |
$2.22B |
5.1% |
| 2018 |
$10.66 |
$46.68B |
$3.79B |
8.1% |
| 2019 |
$10.07 |
$51.34B |
$3.51B |
6.8% |
| 2020 |
$10.93 |
$51.53B |
$3.75B |
7.3% |
| 2021 |
$21.16 |
$58.75B |
$6.96B |
11.8% |
| 2022 |
$19.15 |
$60.23B |
$5.64B |
9.4% |
| 2023 |
$18.96 |
$64.97B |
$5.24B |
8.1% |
| 2024 |
$22.00 |
$70.6B |
$5.76B |
8.2% |
| 2025 |
$28.38 |
$75.6B |
$6.78B |
9% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$30.27 |
$29.18 – $31.41 |
$78.6B |
$77.14B – $80.09B |
16 |
| 2027 |
$33.30 |
$32.20 – $34.43 |
$82.38B |
$81.15B – $84.38B |
16 |
| 2028 |
$37.30 |
$35.61 – $38.71 |
$86.9B |
$86.76B – $87.04B |
7 |
| 2029 |
$42.58 |
$41.58 – $43.93 |
$92.67B |
$91B – $94.93B |
2 |
| 2030 |
$49.36 |
$48.21 – $50.93 |
$100.42B |
$98.61B – $102.86B |
5 |
